2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
103
Leukemia
53
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Lymphoma
29
Prostatic Neoplasms
28
Leukemia, Monocytic, Acute
26
Leukemia, Erythroblastic, Acute
23
Congenital Abnormalities
23
Leukemia, Myelomonocytic, Acute
22
Leukemia, Megakaryoblastic, Acute
21
Myelodysplastic Syndromes
17
Lymphoma, Non-Hodgkin
17
Lymphoma, Follicular
17
Lymphoma, Large B-Cell, Diffuse
16
Recurrence
14
Lymphoma, Large-Cell, Immunoblastic
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Leukemia, Biphenotypic, Acute
9
Lymphoma, Mantle-Cell
8
Burkitt Lymphoma
7
Breast Neoplasms
7
Anemia, Refractory, with Excess of Blasts
6
Neoplasms
5
Leukemia, Promyelocytic, Acute
5
Hodgkin Disease
5
Blast Crisis
5
Ovarian Neoplasms
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Eosinophilic, Acute
4
Leukemia, Basophilic, Acute
4
Interventions
Cyclophosphamide
23
blinatumomab
18
Cytarabine
16
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Daunorubicin
7
Mercaptopurine
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Drug Therapy
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Mitoxantrone
×
Clear all
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled